AbbVie and Genmab's Epcoritamab Trial Shows PFS Gains, No OS Benefit in DLBCL Patients

AbbVie and Genmab's Phase 3 EPCORE DLBCL-1 trial shows a statistically significant improvement in progression-free survival for patients treated with epcoritamab, but no significant improvement in overall survival. The study enrolled 483 patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for high-dose chemotherapy and autologous stem cell transplant. The data will be submitted for presentation at a future medical meeting.